Track topics on Twitter Track topics that are important to you
Renovis is a science-driven, biopharmaceutical company that seeks to discover, develop and commercialize therapeutics for major medical needs in the areas of neurological and inflammatory diseases. Our goal is to create a sustainable pipeline of first- and best-in-class product candidates that will improve the lives of patients as well as provide superior returns to our investors. We are pursuing this goal by investing strategically in our internal drug discovery activities and by applying our expertise to the selection and acquisition of external programs of equal quality and promise. Over time, we expect this blended approach to yield a balanced portfolio of high-potential product candidates that we can commercialize ourselves or with partners. Our integrated capabilities in small molecule drug discovery, including medicinal chemistry, bioinformatics, molecular biology, and pharmacology, enable us to identify and select drug candidates that meet stringent standards for development. This approach has yielded multiple lead candidates in our preclinical programs for pain and inflammation. Our proprietary preclinical programs are focused on identifying antagonists of selected purinergic receptors as novel potential treatments for a broad spectrum of pain and inflammatory conditions. In addition, we have entered into a collaboration with Pfizer Inc. (Pfizer) to discover and develop product candidates targeting the vanilloid receptor, VR1, for the potential treatment of pain and other diseases and disorders, as well as a collaboration with Genentech, Inc. (Genentech) in the areas of nerve growth and anti-angiogenesis. We currently have more than 60 employees based in South San Francisco, California, who are united in their commitment to translating great science into groundbreaking medicines that improve the lives of patients.
Two Corporate Drive
South San Francisco
United States of America
Phone: (650) 266 1400
Fax: (650) 266 1460
Renovis Surgical Technologies has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its 3D-printed Tesera porous titanium interbody fusion systems.
Renovis Surgical Technologies has announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to market posterior lumbar Tesera porous titanium interbody fusion syst...
Renovis Surgical Technologies' 3D-printed Tesera porous titanium interbody fusion systems have been granted 510(k) clearance -More-
REDLANDS, Calif., Aug. 11, 2017 /PRNewswire/ -- Renovis Surgical Technologies, Inc. announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market pos...
Life Sciences Jobs ...
Life Sciences Jobs ...
Renovis is a science-driven, biopharmaceutical company that seeks to discover, develop and commercialize therapeutics for major medical needs in the areas of neurological and inflammatory diseases. Ou...
We have published hundreds of Renovis news stories on BioPortfolio along with dozens of Renovis Clinical Trials and PubMed Articles about Renovis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Renovis Companies in our database. You can also find out about relevant Renovis Drugs and Medications on this site too.
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...